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Abstract
As the SARS-CoV2 pandemic has progressed, there have been marked geographical differ-
ences in the pace and extent of its spread. We evaluated the association of BCG vaccination
on morbidity and mortality of SARS-CoV2, adjusted for country-specific responses to the
epidemic, demographics and health. SARS-CoV2 cases and deaths as reported by 31 May
2020 in the World Health Organization situation reports were used. Countries with at least
28 days following the first 100 cases, and available information on BCG were included. We
used log-linear regression models to explore associations of cases and deaths with the
BCG vaccination policy in each country, adjusted for population size, gross domestic prod-
uct, proportion aged over 65 years, stringency level measures, testing levels, smoking pro-
portion, and the time difference from date of reporting the 100th case to 31 May 2020. We
further looked at the association that might have been found if the analyses were done at
earlier time points. The study included 97 countries with 73 having a policy of current BCG
vaccination, 13 having previously had BCG vaccination, and 11 having never had BCG vac-
cination. In a log-linear regression model there was no effect of country-level BCG status on
SARS-CoV2 cases or deaths. Univariable log-linear regression models showed a trend
towards a weakening of the association over time. We found no statistical evidence for an
association between BCG vaccination policy and either SARS-CoV2 morbidity or mortality.
We urge countries to rather consider alternative tools with evidence supporting their effec-
tiveness for controlling SARS-CoV2 morbidity and mortality.
Background
The global spread of the novel coronavirus (SARS-CoV2) has been unprecedented, with 188
countries now reporting at least one case by the 25 June 2020. The total number of confirmed
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cases globally has increased rapidly, with 9.3 million people diagnosed with SARS-CoV2 as
reported by the World Health Organization (WHO) [1]. The initial wave of SARS-CoV2 was
linked primarily to travel from affected countries, however subsequent increases are the result
of sustained community transmission [2]. As the pandemic has progressed, there have been
marked geographical differences in the pace and extent of its spread. In the early stages of the
pandemic, exponential growth was predominantly seen in high income countries, while low-
and middle-income countries had not yet seen the same exponential increases in new cases,
often demonstrating longer periods for reaching cumulative milestones e.g. time taken to
reach 100 confirmed cases. Countries like Iran and Netherlands reached 100 confirmed cases
of SARS-CoV2 within 10 days of the first case, however Cambodia took almost 60 days to
reach the same milestone [3].
Considerable underlying variation in drivers of the epidemic may explain observed differ-
ences in morbidity among low- and middle-income countries compared to high-income coun-
tries, such as age distribution, health systems strength and ultimately the varied response to
the epidemic by respective countries including testing rates and stringency of lockdown mea-
sures. One specific theory has been the population-level impact of Bacillus Calmette-Guerin
(BCG) vaccination, which is thought by some to have conferred a degree of protection to
SARS-CoV2 in countries where it was or is currently part of the routine immunization sched-
ule. The BCG vaccine is administered to newborns and offers protection against disseminated
forms of TB in children, including TB meningitis and miliary TB [4]. It contains a live attenu-
ated strain of Mycobacterium bovis, to prevent tuberculosis disease, but it is also used as
immune stimulant in other conditions [5].
Since the introduction of BCG, epidemiological studies have demonstrated that the vaccine
reduced infant mortality independent of its effect on tuberculosis [4, 6, 7]. These beneficial
effects have been called ‘heterologous’ or ‘non-specific’ effects [4] and may offer an explanation
for significant variations in SARS-CoV2 morbidity and mortality in low- and middle-income
countries, many of whom still continue to use BCG. However, the effect of BCG on TB is only
effective in children and this has warranted trials to determine whether revaccination of ado-
lescents could reduce the incidence of TB infection as the effect clearly wanes in adolescents
[8]. Association for protection in elderly is further questioned since intravesicular BCG is an
effective therapy for bladder cancer [9], but infant BCG vaccination has not been associated
with protection against bladder cancer in the elderly.
A few unpublished ecological studies have suggested that there may be an association
between BCG and the SARS-CoV2 epidemic [10, 11], while others have discredited its link to
mortality and morbidity [12]. Countries with and without BCG vaccination policy tend to dif-
fer markedly in terms of their economies, health systems and exposure to infectious diseases
[13]. In addition, these studies all assessed BCG association very early in the pandemic and
likely underestimated confounding, particularly differences in the timing of the epidemic and
temporal responses at a country-level [9]. Other factors that require evaluation include
whether BCG vaccination was recently discontinued, so that most people over 30 years of age
have been vaccinated, the testing rates for COVID affecting case incidence and the age struc-
ture of the population [14].
Overcoming the SARS-CoV2 pandemic will require continued understanding of the disease
and potential innovation on multiple fronts. Disparities in available resources globally necessi-
tate that while we strive to find new interventions, we should consider existing tools. Under-
standing the role of BCG in limiting morbidity and mortality may offer insights into its
renewed use and vaccination status may serve as a factor for risk stratification in the ongoing
response. The aim of our study is to evaluate the association of historical or ongoing BCG vac-
cination on morbidity and mortality of SARS-CoV2, embedded within country-specific
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responses to the epidemic, demographics and health policies. In addition, to understand differ-
ing results observed in various published and unpublished papers, we will evaluate trends in
association as epidemic data accumulated.
Methods
Country selection
The analysis for both cases and deaths was conducted based on reporting of cumulative cases
and deaths by 31 May 2020. In order to give sufficient follow-up time since SARS-CoV-2
became “established” in each country, countries were included if they had reported at least of
SARS-CoV-2 or at least 10 SARS-CoV-2-related deaths by 3 May 2020, giving at least 28 days
of follow up by 31 May 2020. In addition, we excluded countries with no existing information
on BCG as described below and/or a population size <1 million as number of actual cases
would be low in such countries.
Data extraction
Table 1 indicates sources for each indicator that were explored. The data on SARS-CoV2 was
extracted from the daily WHO Situation Reports. SARS-CoV2 cases and deaths as reported by
31 May 2020 on the WHO situation reports were used [15]. SARS-CoV2 testing numbers were
obtained on the 11 June 2020 from the Worldometer website [16].
Information on BCG vaccination policies were obtained from the World BCG Atlas which
is an online BCG database that is hosted by McGill University [13, 17]. Where these data were
not available on the BCG atlas, we searched immunization schedules of countries for informa-
tion, and if BCG was not currently universally used (for five countries), we assumed that it had
never been part of their schedule [18]. These were confirmed by checking the UNICEF esti-
mates of immunisation for these countries [19]. In cases, where the standardized immuniza-
tion schedule could not be found, the countries were removed from the analysis (n = 10).
Immunization coverage in most countries that do have universal access is above 90% and so
that was not considered as a variable for analysis.
For SARS-CoV2 stringency levels, we used the Oxford COVID-19 Government Response
Tracker [20], which classifies country-level stringency levels according to containment and
closure policies, such as school closures and restrictions in movement and determines a strin-
gency index from 1 to 100 on a daily basis for each country. We used the stringency index level
for each country at the date of reporting the 100th confirmed case and then at a date 28 days
post this milestone. Smoking data were obtained from the World Health Organisation [21].
TB incidence was obtained from the 2019 TB Global Report [22]. The raw data on which our
analyses are based is available in Supplementary Tables.
Data analysis
BCG status was categorized to current BCG policy, previous BCG policy (where it was in place
for greater than 30 years) and no BCG policy (where it was never used or used for less than 30
years) [13]. The overall proportion smoking was determined by using the proportions of males
and females in the population and the proportion of smokers in each gender group. We calcu-
lated the country-specific time difference from the date of the 100th reported case to 31st May
2020 to control for the stage of the epidemic that each country was in.
We log-transformed the continuous outcome variables of country-level cases and deaths,
using log-linear regression to examine the relationship between the outcome (COVID cases
and mortality) and BCG status in univariable models. In the earliest stages of an epidemic the
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population size of a country is not a determinant of initial spread. However, as the epidemic
progresses, the population size can become a strong determinant of numbers of cases and
deaths. Hence, we used the numbers of cases and numbers of deaths as outcomes, rather than
the incidence rate and mortality rate. We adjusted for the population size in regression models
by using the log of the population size, and so a regression coefficient for log population size of
zero would correspond to no association between cases or deaths and population size, while a
regression coefficient of 1 would be equivalent to using incidence and mortality rates as the
outcomes.
We constructed adjusted models by including variables that confounded the associations
between outcomes and BCG status. We built these final models adding one by one each
Table 1. Indicators included in article and their sources.
Indicator Source of information Organisation





Date of 1st case WHO situation report World Health Organisation
Date of 10th death WHO situation report World Health Organisation
28 days after 10th death WHO situation report World Health Organisation
Testing numbers (on 29th April) Worldometers https://www.worldometers.info/coronavirus/
#countries
Number of people infected by 28 days post
10th death
WHO situation report World Health Organisation
Number of people dead by 28 days post 10th
death
WHO situation report World Health Organisation
BCG indicators Availability of a current BCG policy BCG atlas: http://www.bcgatlas.org/index.php Mc Gill International TB Centre
Date/year of first BCG vaccine
administration after policy implementation
BCG atlas Mc Gill International TB Centre
Date/year of last BCG vaccine
administration after policy implementation
BCG atlas Mc Gill International TB Centre
Coverage of BCG BCG atlas Mc Gill International TB Centre
Strain of the Bacilli in the vaccine BCG atlas Mc Gill International TB Centre
Age at administration BCG atlas Mc Gill International TB Centre
Other country level
indicators
Restrictions—stringency level at 10th death https://www.bsg.ox.ac.uk/research/research-projects/
coronavirus-government-response-tracker
University of Oxford/ Blatvatnik
School of Government




University of Oxford/ Blatvatnik
School of Government
World Bank income level (High, Medium,
Low)
https://www.worldbank.org/en/country World Bank
Gross Domestic Product https://www.worldbank.org/en/country World Bank
Net immigration https://www.worldbank.org/en/country World Bank





Population of country https://www.worldbank.org/en/country World Bank
Population density of country https://www.worldbank.org/en/country World Bank
Proportion of population over 65 years https://www.worldbank.org/en/country World Bank
TB incidence rate World TB report 2019 World Health Organisation
TB mortality rate World TB report 2019 World Health Organisation
Medical doctors per capita https://www.worldbank.org/en/country World Bank
Nurses per capita https://www.worldbank.org/en/country World Bank
% smoking among men https://apps.who.int/gho/data/node.main.65 World Health Organisation
% smoking among women https://apps.who.int/gho/data/node.main.65 World Health Organisation
https://doi.org/10.1371/journal.pone.0243707.t001
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variable starting with the one that demonstrated the strongest confounding of the associations.
Other data considered, but not included in the model based on a lack of observed association
with SARS-CoV2 cases or mortality, were TB incidence rates per country for 2019, HIV preva-
lence, medical doctors per capita, nurses per capita, population density, proportion of urban
population, net immigration, number of air passengers per year and stringency index at 28
days.
Finally, we repeated the log linear regression models for each of SARS-CoV2 cases and
deaths using the numbers of SARS-CoV2 cases and deaths reported at three prior time-points
during the epidemic (mid-April, end of April, and. mid-May 2020) to better understand com-
parisons with results from previously unpublished studies. Analyses were performed in Stata
version 14 [23] and maps were drawn using ArcMap version 10.7.1 [24]. Unadjusted regres-
sion coefficients are presented, with a regression coefficient of zero indicating no association.
Results
There were 107 countries for which complete data on the total SARS-CoV2 cases were avail-
able end of May 2020. Data sources are summarised in Table 1. Ten countries were excluded
for having a population <1 million or no data on BCG vaccination, leaving 97 countries in the
analysis (Fig 1). Country-level characteristics stratified by BCG status are shown in S1–S3
Tables.
Table 2 shows the log-linear regression models for cases and deaths at 31 May 2020 adjusted
for population, gross domestic product, age under 65, stringency measures, testing levels,
smoking proportion, and the time difference from date of 100th reported case to 31 May.
Upon adjustment, there was no statistical evidence for an association between number of cases
and BCG status (Table 2). However, positive associations were observed with population size
(coefficient per log increase: 0.93; 95% CI: 0.54, 1.13, p-value<0.0001) and tests per capita
(coefficient per log increase 0.72; 95% CI: 0.45, 0.99, p-value<0.0001). An inverse relationship
between SARS-CoV2 cases and strength of stringency measures at 100 cases was observed
(coefficient: -0.02; 95% CI: -0.03, -0.003, p-value = 0.01). The level of stringency measures
implemented at the 100th case for each country are visualised in Fig 2 showing countries in
Fig 1. Flow chart describing country selection.
https://doi.org/10.1371/journal.pone.0243707.g001
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red having a low level of stringency measures (>25%) and in green, a higher level of stringency
measures (>75%) implemented.
Similarly, for deaths, there was no statistical evidence for an association between number of
deaths and BCG status after adjusting for selected variables (Table 2). However, positive asso-
ciations were observed with population size (coefficient per log increase: 1.20, 0.69, 1.72,
p-value<0.0001), proportion of population aged over 65 years (coefficient per percentage
point increase 0.08, 95%CI 0.01, 0.14; p-value = 0.02), and tests per capita (coefficient per log
increase 0.44, 95% CI 0.08, 0.80, p-value = 0.02). Weak statistical evidence was seen for an
Table 2. Country-level adjusted associations between BCG status and log-transformed number of SARS-CoV2 cases and deaths at 31 May 2020.
SARS-CoV2 cases (n = 85) SARS-CoV2 deaths (n = 84)
Estimate 95% CI p-value Estimate 95% CI p-value
BCG vaccination status
Current Ref - - Ref - -
Ever -0.17 -1.00, 0.65 0.68 0.35 -0.74, 1.44 0.52
Never -0.48 -1.28, 0.33 0.24 0.06 -1.01, 1.12 0.92
Controlled for:
Log gross domestic product per capita ($)1 -0.02 -0.41, 0.37 0.93 -0.10 -0.62, 0.42 0.70
Log population size (millions) 2 0.93 0.54, 1.31 <0.0001 1.20 0.69, 1.72 <0.0001
Proportion of population over 65 years (%)3 -0.03 -0.08, 0.02 0.20 0.08 0.01, 0.14 0.02
Log tests per capita4 0.72 0.45, 0.99 <0.0001 0.44 0.08, 0.80 0.02
Stringency level at 100th case -0.02 -0.03, -0.003 0.01 -0.01 -0.03, 0.002 0.08
Smoking prevalence5 -0.01 -0.03, 0.01 0.36 -0.01 -0.04, 0.02 0.48
Difference between date of 100th case and end of May 2020 (days) 0.04 -0.01, 0.08 0.10 -0.04 0.10, 0.02 0.21
1Estimates as at 2018;
2Estimates as at 2018;
3Estimates as at 2018;
4Estimates as at 11 June 2020;
5Estimates as at 2018
https://doi.org/10.1371/journal.pone.0243707.t002
Fig 2. Stringency measures applied to selected countries after 100 reported COVID-19 cases.
https://doi.org/10.1371/journal.pone.0243707.g002
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inverse relationship between SARS-CoV2 deaths and strength of stringency measures at 100
cases (coefficient: -0.01, 95% CI: -0.03, 0.002, p-value = 0.08).
To understand why previous studies reported an association, we show the univariable asso-
ciations between each of cases and deaths with BCG policy at four time points from mid-April
to end of May 2020 (Fig 3). We show a trend for a weakening effect on confirmed SARS-CoV2
cases and deaths from mid-April to end of May 2020. These are further explored in multivari-
able models for cases and deaths at different time points in Tables 3 and 4, with no statistical
evidence seen for association between either cases or deaths and BCG policy at any of the time
points in adjusted models.
Discussion
Using data from 97 countries, we evaluated the effect of BCG vaccination policy on SARS-
CoV2 morbidity and mortality and found no statistical evidence for an association, with
strengths of associations weakening over time as the epidemic progressed. In addition, when
evaluating associations with morbidity and mortality at multiple time points over a two-
month period, we observed little variation in magnitude and direction of association for all
variables except BCG vaccination policy, suggesting that multiple country-level factors may
likely underpin the SARS-CoV2 epidemic rather than BCG vaccination policy.
The presence of confounders such as older age, gross domestic product, differential testing
and population size were investigated. Similar to other studies which showed higher mortality
in older age groups>65 years, our study reported this association which confirms age as a
major risk factor for COVID-19 morbidity and mortality at a country level [10, 12]. Although
high income countries have robust healthcare systems, the income level of a country was not
identified as a confounding factor that explained the association between BCG vaccination
and COVID-19 risk. The level of healthcare preparedness including the number of tests con-
ducted was likely to determine the morbidity and mortality cases.
In our ecological analysis, we found that BCG vaccination policy did not influence the mag-
nitude of SARS-CoV2 morbidity and mortality at a country-level. This was confirmed by
Fig 3. Univariable associations between cases and deaths with BCG policy at four time points from mid-April to
end of May 2020.
https://doi.org/10.1371/journal.pone.0243707.g003
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observational studies in Sweden [25], Israel [26] and Germany [27] which used individual level
data to test this association. In Sweden, BCG vaccination did not reduce cases or hospitaliza-
tions due to COVID-19 in cohorts whose recorded births were before and after 1975 [25]. In
Israel, there was no association after comparison between rates of coronavirus PCR test
Table 4. Country-level adjusted associations between BCG status and SARS-CoV2 deaths.
Mid-April 2020 (n = 84) End of April 2020 (n = 84) Mid-May 2020 (n = 84)
Estimate 95% CI p-value Estimate 95% CI p-value Estimate 95% CI p-value
BCG vaccination status
Current Ref - - Ref - - Ref - -
Ever 0.55 -0.48, 1.59 0.29 0.62 -0.38, 1.61 0.22 0.50 -0.55, 1.55 0.34
Never 0.50 -0.51, 1.51 0.33 0.47 -0.50, 1.45 0.33 0.27 -0.75, 1.30 0.60
Controlled for:
Log gross domestic product per capita ($)1 -0.17 -0.66, 0.32 0.50 -0.17 -0.65, 0.30 0.47 -0.15 -0.65, 0.35 0.55
Log population size (millions) 1.01 0.53,1.50 <0.0001 1.16 0.69, 1.62 <0.0001 1.21 0.71, 1.69 <0.0001
Proportion of population over 65 years (%) 0.08 0.02, 0.14 0.01 0.10 0.05, 0.16 0.001 0.10 0.04, 0.16 0.002
Log tests per capita 0.44 0.09, 0.78 0.01 0.43 0.10, 0.76 0.01 0.43 0.08, 0.77 0.02
Stringency level at 100th case -0.01 -0.02, 0.01 0.24 -0.01 -0.03, 0.004 0.13 -0.01 -0.03, 0.003 0.10
Smoking prevalence -0.001 -0.03, 0.03 0.96 -0.01 -0.03, 0.02 0.64 -0.01 -0.04, 0.02 0.51
Difference between date of 100th case and end of May
2020 (days)
-0.08 -0.13, -0.02 0.01 -0.05 -0.11, 0.0004 0.05 -0.05 -0.10, 0.01 0.13
1Estimates as at 2018;
2Estimates as at 2018;
3Estimates as at 2018;
4Estimates as at 11 June 2020;
5Estimates as at 2018
https://doi.org/10.1371/journal.pone.0243707.t004
Table 3. Country-level adjusted associations between BCG status and log-transformed number of SARS-CoV2 cases.
Mid-April 2020 (n = 85) End of April 2020 (n = 85) Mid-May 2020 (n = 85)
Estimate 95% CI p-value Estimate 95% CI p-value Estimate 95% CI p-value
BCG vaccination status
Current Ref - - Ref - - Ref - -
Ever 0.21 -0.42, 0.85 0.51 -0.02 -0.72, 0.69 0.96 -0.10 -0.88, 0.68 0.79
Never 0.25 -0.36, 0.87 0.42 -0.11 -0.80, 0.58 0.75 -0.30 -1.07, 0.46 0.43
Controlled for:
Log gross domestic product per capita ($)1 -0.17 -0.48, 0.14 0.28 -0.09 -0.43, 0.24 0.58 -0.08 -0.45, 0.29 0.67
Log population size (millions) 0.85 0.56, 1.15 <0.0001 0.87 0.53, 1.20 <0.0001 0.92 0.56, 1.29 <0.0001
Proportion of population over 65 years (%) 0.04 -0.001, 0.07 0.06 0.02 -0.02, 0.06 0.37 -0.01 -0.05, 0.04 0.79
Log tests per capita 0.65 0.44, 0.85 <0.0001 0.68 0.45, 0.91 <0.0001 0.71 0.44, 0.96 <0.0001
Stringency level at 100th case -0.01 -0.02, 0.001 0.10 -0.01 -0.02, -0.001 0.03 -0.01 -0.03, -0.003 0.01
Smoking prevalence -0.01 -0.02, 0.01 0.57 0.01 -0.03, 0.01 0.42 -0.01 -0.03, 0.01 0.38
Difference between date of 100th case and end of May
2020 (days)
0.07 0.04, 0.10 <0.0001 0.06 0.02, 0.09 <0.001 0.05 0.005, 0.09 0.03
1Estimates as at 2018;
2Estimates as at 2018;
3Estimates as at 2018;
4Estimates as at 11 June 2020;
5Estimates as at 2018
https://doi.org/10.1371/journal.pone.0243707.t003
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positivity among Israelis with symptoms suspicious for COVID-19 who did and did not
receive BCG vaccination as part of routine childhood immunization in the early 1980s [26].
Lastly, Lindestam Arlehamn et al showed no correlation between BCG coverage and the
mortality while comparing COVID-19 deaths Eastern and Western Germany states [27]. A
recent systematic review and meta-analysis that evaluated BCG vaccination on SARS-CoV2
infection among 13 full-text articles (12 were not peer-reviewed), reported a similar conclu-
sion despite significant heterogeneity in study-specific findings [28]. Our findings demon-
strated that timing of the analyses influenced BCG association, a factor which may explain
why earlier studies showed some association, however as more data became available, its sig-
nificance resolved. The magnitude of the SARS-CoV2 epidemic has and will likely be deter-
mined by country-level responses. Initial and ongoing suppression strategies, effective
testing and tracing approaches coupled with strong healthcare systems, will ultimately flatten
the epidemic curve. The use of BCG vaccination may not be associated with protection
against SARS-CoV2, however, the importance of its use as a key TB prevention strategy
should not be neglected. We thus support recent calls by the TB community for responsible
stewardship of BCG and its continued use in populations against TB, where substantial
proven benefits exist [29].
Notwithstanding the limited biological inference of BCG protection against SARS-CoV2,
many countries that have succumbed considerably in terms of morbidity and mortality have a
previous BCG vaccination policy or are currently vaccinating infants. Our study found that
almost 90% of countries we evaluated implemented historic or current BCG vaccination pol-
icy. In addition, countries classified as previous or no BCG vaccination policy are all in high-
income settings, with the exception of Lebanon. If we assume BCG was capable of conferring
protection against SARS-CoV2 morbidity and mortality, infant vaccination would result in
staggered protection over time among age groups. Many countries introduced BCG vaccina-
tion between 1940 and 1950’s, meaning that currently, individuals aged between 60 and 70
years would have benefitted from any potential protection it conferred to SARS-CoV2. In con-
trast, older age have been identified as one of the highest risk groups for being diagnosed or
dying from SARS-CoV2 [30]. These data negate the causality that BCG may be conferring pro-
tection to SARS-CoV2 morbidity and mortality, at least in the older age groups.
The selection of outcome also seems to influence different conclusions on the protective
effect of BCG vaccination. Some studies have suggested that SARS-CoV2 mortality alone may
be influenced by BCG [31], however other studies have demonstrated that the combination of
morbidity and mortality might be affected [32]. Our data showed no significant BCG effect
when modelling morbidity or mortality outcomes and controlling for relevant confounding
factors. Although there were differences in the degree of BCG association by outcome, this
might likely be attributed to challenges in adjusting for confounding. Risk factors associated
with SARS-CoV2 morbidity and transmission are challenging to control for each country as
variations in environmental, individual, health system and behavioural patterns are not easy to
capture. Similarly, factors associated with mortality at a country-level are complex, likely influ-
enced by events earlier in the SARS-CoV2 care cascade. Thus, while we await evidence from
ongoing randomized controlled trials (RCT) assessing various study outcomes, we cannot
derive definitive conclusions on the impact of BCG on SARS-CoV2.
Our study has a number of strengths which refine current evidence around BCG vaccina-
tion and its impact on SARS-CoV2. Firstly, we conducted our analysis on a large number of
countries representing a spectrum of low- to high-income countries and BCG usage. Secondly,
we provided estimates of BCG association on morbidity and mortality over a two-month time
horizon. This approach enabled more countries to reach significant milestones in their epi-
demic for comparison and allowed us to observe temporal changes in association. Thirdly, we
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evaluated a number of factors implicated in SARS-CoV2 morbidity and mortality; this
improved control of confounding that may have influenced previous estimates. Fourthly, we
evaluated the effect of changes in restrictions following the 100th case and 10th death per coun-
try on subsequent SARS-CoV2 morbidity and mortality. Lastly, we accounted for variations in
the spread of SARS-CoV2 by including a variable which measured the time taken from the
100th case to the analysis cut-off per country in the final model.
Our use of an ecological study design has introduced limitations to our findings. Firstly, we
used BCG policy estimates in relation to infant vaccination, however there are variations to
policy. In some countries, infant BCG vaccination may not be policy, however vaccination is
targeted at individuals considered high-risk for TB or originating from high-burden settings;
we did not however identify any literature to support this. In addition, we also noted signifi-
cant variations in the duration of BCG coverage, timing of coverage, strain-type used, all of
which make comparisons difficult. Secondly, our estimates of morbidity and mortality,
although based on country-level information, is likely under-estimated. Evidence has shown
that individuals are transmitting virus in the absence of known SARS-CoV2 symptoms, the
result of which has made quantifying morbidity challenging for many countries, particularly
those with limited resources, however we have attempted to adjust for possible confounding
by including the number of tests per capita for each country. Cause of death may be misclassi-
fied particularly since SARS-CoV2 mortality is exacerbated among groups with comorbidities
such as cardiovascular or other respiratory illnesses. Finally, the use of an ecological design
introduced confounding that may not be have been controlled for. This is our biggest and
most important study limitation, equally shared by some unpublished studies who have
attempted to answer this question. To address this, we did include a variety of factors that
might confound the protective effect of BCG vaccination; this was based on ongoing SARS-
CoV2 literature and those identified as shortcomings in unpublished studies on this topic so
far.
Conclusion
The current SARS-CoV2 pandemic has challenged public health response globally. The
unknown nature of the disease coupled with high morbidity and mortality rates has forced us
to consider existing tools while we develop effective treatment and prevention strategies.
Repurposing tools are not uncommon as they provide shorter time to implementation, how-
ever their use must be informed by evidence. In contrast to some unpublished studies, we
found no association between BCG vaccination policy on SARS-CoV2 morbidity and mortal-
ity at country-level and assert that any observed affect may likely be due to uncontrolled con-
founding. It may be that BCG vaccination at birth does not confer immunity in later life,
where it anecdotally is more likely to impact SARS-CoV2 morbidity and mortality rates, but
that does not exclude the possibility that BCG vaccination later in life may be effective. Due to
ecological fallacy, we cannot conclude that BCG vaccination is not associated with COVID-19
morbidity and mortality at an individual level but our findings at a national level did not find
an association. While we anticipate evidence from ongoing BCG vaccination randomized con-
trolled trials (RCTs), we urge countries to rather consider alternative tools with evidence sup-
porting their effectiveness for controlling SARS-CoV2 morbidity and mortality such as
ongoing randomized controlled trials on prevention of COVID-19 conducted in USA, Nether-
lands and Australia on more than 6,000 healthcare workers. The renewed prominence of BCG
vaccination should also serve as a reminder for the global community that while our focus may
be captured by SARS-CoV2, tuberculosis remains a significant problem, deserving greater
attention and should not be neglected during this period.
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